MX375152B - Composición de espuma de halobetasol y método de uso de la misma. - Google Patents

Composición de espuma de halobetasol y método de uso de la misma.

Info

Publication number
MX375152B
MX375152B MX2018007343A MX2018007343A MX375152B MX 375152 B MX375152 B MX 375152B MX 2018007343 A MX2018007343 A MX 2018007343A MX 2018007343 A MX2018007343 A MX 2018007343A MX 375152 B MX375152 B MX 375152B
Authority
MX
Mexico
Prior art keywords
composition
halobetasol
foam
same
corticosteroid
Prior art date
Application number
MX2018007343A
Other languages
English (en)
Other versions
MX2018007343A (es
Inventor
James D Hammer
Robert T Gauthier
Original Assignee
Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57543101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375152(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Therapeutics Inc filed Critical Therapeutics Inc
Publication of MX2018007343A publication Critical patent/MX2018007343A/es
Publication of MX375152B publication Critical patent/MX375152B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona una composición y método para tratar varias enfermedades de la piel. La composición se formula como una composición espumable e incluye el corticosteroide halobetasol.
MX2018007343A 2015-12-15 2016-11-30 Composición de espuma de halobetasol y método de uso de la misma. MX375152B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267749P 2015-12-15 2015-12-15
PCT/IB2016/057227 WO2017103719A1 (en) 2015-12-15 2016-11-30 Halobetasol foam composition and method of use thereof

Publications (2)

Publication Number Publication Date
MX2018007343A MX2018007343A (es) 2019-03-14
MX375152B true MX375152B (es) 2025-03-06

Family

ID=57543101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007343A MX375152B (es) 2015-12-15 2016-11-30 Composición de espuma de halobetasol y método de uso de la misma.

Country Status (14)

Country Link
US (2) US10857159B2 (es)
EP (1) EP3389631B1 (es)
JP (1) JP2018538327A (es)
KR (1) KR20180098300A (es)
CN (1) CN108601733B (es)
AU (1) AU2016372789B2 (es)
BR (1) BR112018012349A2 (es)
CA (1) CA3008753C (es)
EA (1) EA035300B1 (es)
ES (1) ES2770325T3 (es)
MX (1) MX375152B (es)
PH (1) PH12018501278A1 (es)
SG (1) SG11201805109YA (es)
WO (1) WO2017103719A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3251657A1 (en) * 2016-05-30 2017-12-06 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
WO2018020385A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Touch-free topical spray of halobetasol

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
CN1086580C (zh) * 1998-03-23 2002-06-26 阎丽 一种皮炎止痒软膏
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US7186416B2 (en) * 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US20050069499A1 (en) * 2003-09-25 2005-03-31 Moshe Arkin Foamable compositions, processes of preparing same and uses thereof
EP2046121B1 (en) * 2006-07-14 2012-08-22 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
MX354480B (es) * 2009-02-12 2018-03-07 Prec Dermatology Inc Star Composiciones espumables de peróxido de benzoilo para administración tópica.
PT2400951T (pt) * 2009-02-25 2018-11-26 Mayne Pharma Llc Composições de espuma tópica
MX2011011206A (es) * 2009-04-24 2012-02-28 Johnson & Johnson Consumer Composiciones topicas estables para derivados de 1,2,4-tiadiazol.
CN101926765A (zh) * 2009-06-24 2010-12-29 天津金耀集团有限公司 一种糠酸莫米松泡沫剂组合物
US20110212035A1 (en) * 2010-02-26 2011-09-01 Collegium Pharmaceutical, Inc. Emollient foams for treatment of dermatoses
CA2854449A1 (en) * 2011-11-03 2013-05-10 Precision Dermatology, Inc. Stable dermatological aerosol foams utilizing reactive propellants
WO2013110077A1 (en) * 2012-01-19 2013-07-25 Hybrid Medical, Llc Topical therapeutic formulations
US20140079648A1 (en) * 2012-09-14 2014-03-20 Gojo Industries, Inc. Antimicrobial alcoholic foamable compositions
JP6113019B2 (ja) * 2013-08-07 2017-04-12 株式会社ディスコ ウエーハの分割方法
BR112016006830A2 (pt) * 2013-09-25 2017-08-01 Sun Pharmaceutical Ind Ltd composição de spray tópico de halobetasol, sistema de distribuição para a administração da composição, processo para a preparação de uma composição de spray tópico, método para o tratamento de condições de pele tópicas
KR20180098299A (ko) * 2015-12-15 2018-09-03 테라퓨틱스 인코퍼레이티드 코르티코스테로이드 함유 발포체 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
SG11201805109YA (en) 2018-07-30
NZ743577A (en) 2025-02-28
EA201891351A1 (ru) 2019-01-31
WO2017103719A1 (en) 2017-06-22
AU2016372789B2 (en) 2021-12-16
EA035300B1 (ru) 2020-05-26
BR112018012349A2 (pt) 2018-12-04
US20190365782A1 (en) 2019-12-05
JP2018538327A (ja) 2018-12-27
CA3008753C (en) 2023-06-20
MX2018007343A (es) 2019-03-14
US10857159B2 (en) 2020-12-08
EP3389631B1 (en) 2019-11-13
US20170165275A1 (en) 2017-06-15
CN108601733A (zh) 2018-09-28
AU2016372789A1 (en) 2018-07-05
ES2770325T3 (es) 2020-07-01
EP3389631A1 (en) 2018-10-24
KR20180098300A (ko) 2018-09-03
CN108601733B (zh) 2021-11-09
PH12018501278A1 (en) 2019-01-28
CA3008753A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
IL282372A (en) Haploid induction compositions and methods for use therefor
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
CL2017003486A1 (es) Lactamas bicíclicas y métodos de uso de las mismas
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2024010027A (es) Anticuerpos contra el vih ampliamente neutralizantes y metodos de uso de ellos.
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
MX391040B (es) Formulacion de alta concentracion.
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
MX390653B (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lúpica.
CO2019006113A2 (es) Pulverizador
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
PH12018501277A1 (en) Corticosteroid containing foam compositions and method of manufacture thereof
MX375152B (es) Composición de espuma de halobetasol y método de uso de la misma.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
MX388476B (es) Vidrio de seguridad y procedimiento para su obtención.

Legal Events

Date Code Title Description
FG Grant or registration